Anti-CD20 therapy and autoimmune disease: Therapeutic opportunities and evolving insights

Frontiers in Bioscience

Volumn 12, Issue 6, 2007, Pages 2194-2206

  Silverman, Gregg J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Apoptosis; Autoimmunity; CD 20; Drug; Host immunity; Immune system; RA; Review; Rheumatoid arthritis; SLE; Systemic lupus erythromatosus; Therapy; Tolerance

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL LINEAGE; DRUG EFFECT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL LINEAGE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SELF TOLERANCE;

EID: 34247558458     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2222     Document Type: Article

References (76)

1. G. J Silverman and S. Weisman: Rituximab Therapy and Autoimmune Disorders: Prospects for anti-B cell therapy. Arthritis Rheum 48(6), 1484-92 (2003) (Pubitemid 36682354)
2. J. C. Edwards and G. Cambridge: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40(2), 205-11 (2001)
3. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens and T. Shaw: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25), 2572-81 (2004) (Pubitemid 38758544)
4. F. Martin and A.C. Chan: B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24, 467-96 (2006)
5. G. J. Silverman and D.A. Carson: Role of B lymphocytes in Rheumatoid Arthritis. Arth Res Therapy 5 (suppl 4), 1-6 (2003)
6. D. van Zeben, J.M. Hazes, A.H. Zwinderman, A. Cats, E.A. van der Voort and F.C. Breedveld: Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 51(9), 1029-35 (1992)
7. P.B. Brown, F.A. Nardella and M. Mannik: Human complement activation by self-associated IgG rheumatoid factors. Arthritis Rheum 25(9), 1101-7 (1982) (Pubitemid 12028784)
8. S. Rantapaa-Dahlqvist, B.A. de Jong, E. Berglin, G. Hallmans, G. Wadell, H. Stenlund, U. Sundin and W. J. van Venrooij: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48(10), 2741-9 (2003) (Pubitemid 37280601)
9. P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, A.J. Racewicz, R.F. van Vollenhoven, N. F. Li, S. Agarwal, E. W. Hessey and T.M. Shaw: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, doseranging trial. Arthritis Rheum 54(5), 1390-400 (2006)
10. S.B. Cohen, M. Greenwald, M.R. Dougados, P. Emery, R. Furie, T. Shaw and M.C. Totoritis: Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF therapies (REFLEX study). Arth Rheum 52 Suppl 9:S677(Abstract) (2005)
11. D.B. Cines and V.S. Blanchette: Immune thrombocytopenic purpura. N Engl J Med 346(13), 995-1008 (2002)
12. R. McMillan: The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin Hematol 37(1 Suppl 1), 5-9 (2000) (Pubitemid 30080232)
13. M. Kuwana, Y. Okazaki, J. Kaburaki, Y. Kawakami and Y. Ikeda: Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 168(7), 3675-82 (2002) (Pubitemid 34250440)
14. K. Kojouri, S.K. Vesely, D.R. Terrell and J.N. George: Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104(9), 2623-34 (2004) (Pubitemid 39434940)
15. S. Hall, J.L. McCormick, Jr, P.R. Greipp, C.J. Michet Jr and C.H. McKenna: Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med 102(3), 325-8 (1985)
16. W.R. Bell Jr: Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura. Semin Hematol 37(1 Suppl 1), 22-5 (2000) (Pubitemid 30080235)
17. M.N. Saleh, J. Gutheil, M. Moore, P.W. Bunch, J. Butler, L. Kunkel, A.J. Grillo-Lopez, and A.F. LoBuglio: A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27(6 Suppl 12), 99-103 (2000) (Pubitemid 32164602)
18. N. Cooper, R. Stasi, S. Cunningham-Rundles, M.A. Feuerstein, J.P. Leonard, S. Amadori and J.B. Bussel: The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125(2), 232-9 (2004) (Pubitemid 38534976)
19. Diagnosis and treatment of idiopathic thrombocytopenic purpura. American Society of Hematology ITP Practice Guideline Panel. Am. Fam. Physician 54, 2437-47 (1996)
20. C. Kneitz, M. Wilhelm and H.P. Tony: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 206(5), 519-27 (2002) (Pubitemid 36192911)
21. Y. Ioannou and D.A. Isenberg: Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 78(924), 599-606 (2002) (Pubitemid 35333066)
22. M. Petri: Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 13(5), 366-71 (2004) (Pubitemid 38788498)
23. J. Schiffenbauer, B. Hahn, M.H. Weisman and L.S. Simon: Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum 50(8), 2415-2422 (2004) (Pubitemid 39062699)
24. R.J. Looney, J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, L.J. Arend, J.A. Sloand, J. Rosenblatt and I. Sanz: B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50(8), 2580-2589 (2004) (Pubitemid 39062719)
25. M.J. Leandro, J.C. Edwards, G. Cambridge, M.R. Ehrenstein and D.A. Isenberg: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 146(10), 2673-2677 (2002) (Pubitemid 36118931)
26. P. Sfikakis, J.N. Boletis, L. Lionaki, V. Vigklis, K.G. Fragiadaki, A.I. Iniotaki, and H.M. Moutsopoulos: Remission of proliferative lupus nephritis following anti-B cell therapy is preceded by downregulation of the T cell costimulatory molecule CD40-Ligand. Arthritis Rheum 52(2):501-13 (2005) (Pubitemid 40216314)
27. J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, I. Sanz, J. Rosenblatt and R.J. Looney: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48(2), 455-9 (2003) (Pubitemid 36278014)
28. J.H. Anolik, J. Barnard, A.I. Cappione, A. Pugh-Bernard, F. Young, J. Looney and I. Sanz: Effects of Rituximab on B Cells in Human SLE. Arthritis Rheum 48(suppl 9); (Abstract) (2003)
29. A.-S. Rouzière, C. Kneitzl, T. Dörner and H.-P. Tony: B-Cell Depletion by Anti-CD20 Antibody Treatment in Rheumatoid Arthritis modulates the B-Cell Repertoire Arthritis Rheum 48(suppl 9); (Abstract) (2003)
30. G.P. Sims, R. Ettinger, Y. Shirota, C.H. Yarboro, G.G. Illei and P.E. Lipsky: Identification and characterization of circulating human transitional B cells. Blood 105(11), 4390-8 (2005) (Pubitemid 40720786)
31. C. Wehr, H. Eibel, M. Masilamani, H. Illges, M. Schlesier, H.H. Peter and K. Warnatz: A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol 113(2), 161-71 (2004) (Pubitemid 39296849)
32. G.J. Silverman: Therapeutic B cell depletion and regeneration in rheumatoid arthritis: Emerging patterns and paradigms. Arthritis Rheum 54 (8), 2356-2367 (2006) (Pubitemid 44204995)
33. J.H. Kehrl, A. Riva, G.L. Wilson and C. Thevenin: Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today 15(9), 432-6 (1994) (Pubitemid 24272188)
34. J. Anolik, R.J. Looney, A. Bottaro, I. Sanz and F. Young: Down-regulation of CD20 on B cells upon CD40 activation. Eur J Immunol 33(9), 2398-409 (2003) (Pubitemid 37138972)
35. I. Semac, C. Palomba, K. Kulangara, N. Klages, G. van Echten-Deckert, B. Borisch and D.C. Hoessli: Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 63(2), 534-40 (2003) (Pubitemid 36152518)
36. A.V. Filatov, I.B. Shmigol, G.V. Sharonov, A.V. Feofanov and Y. Volkov: Direct and indirect antibodyinduced TX-100 resistance of cell surface antigens. Immunol Lett 85(3), 287-95 (2003) (Pubitemid 36349034)
37. H. Kono, C. Kyogoku, T. Suzuki, N. Tsuchiya, H. Honda, K. Yamamoto, K. Tokunaga and Z. Honda: FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet 14(19), 2881-92 (2005) (Pubitemid 41418793)
38. G. Cassese, S. Arce, A.E. Hauser, K. Lehnert, B. Moewes, M. Mostarac, G. Muehlinghaus, M. Szyska, A. Radbruch and R.A. Manz: Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 171(4), 1684-90 (2003) (Pubitemid 36966450)
39. T. Nakayama, K. Hieshima, D. Izawa, Y. Tatsumi, A. Kanamaru and O. Yoshie: Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 170(3), 1136-40 (2003) (Pubitemid 36139476)
40. A.E. Hauser, G.F. Debes, S. Arce, G. Cassese, A. Hamann, A. Radbruch and R.A. Manz: Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol 169(3), 1277-82 (2002) (Pubitemid 34809169)
41. A. Avigdor, P. Goichberg, S. Shivtiel, A. Dar, A. Peled, S. Samira, O. Kollet, R. Hershkoviz, R. Alon, I. Hardan, H. Ben-Hur, D. Naor, A. Nagler and T. Lapidot: CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103(8), 2981-9 (2004) (Pubitemid 38451670)
42. G. Cassese, S. Lindenau, B. de Boer, S. Arce, A. Hauser, G. Riemekasten, C. Berek, F. Hiepe, V. Krenn, A. Radbruch and R.A. Manz: Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 31(9), 2726-32 (2001) (Pubitemid 32898740)
43. H. Sekine, H. Watanabe and G. S. Gilkeson: Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J Immunol 172(6), 3913-21 (2004) (Pubitemid 38337979)
44. L.D. Erickson, L.L. Lin, B. Duan, L. Morel and R.J. Noelle: A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci (USA) 100(22), 12905-10 (2003) (Pubitemid 37339998)
45. T. Dorner and P.E. Lipsky: Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus. Lupus 13(5), 283-9. (2004) (Pubitemid 38788484)
46. Herman, J. H., Bradley, J., Ziff, M., and Smiley, J. D. Response of the rheumatoid synovial membrane to exogenous immunization. J Clin Invest 50(2), 266-73 (1971)
47. T. Seki, J. Selby, T. Haupl and R. Winchester: Use of differential subtraction method to identify genes that characterize the phenotype of cultured rheumatoid arthritis synoviocytes. Arthritis Rheum 41(8), 1356-64 (1998) (Pubitemid 28373114)
48. J. Dechanet, P. Merville, I. Durand, J. Banchereau and P. Miossec: The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. J Clin Invest 95(2), 456-63 (1995)
49. J.A. Burger, N.J. Zvaifler, N. Tsukada, G.S. Firestein and T.J. Kipps: Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 107(3), 305-15 (2001) (Pubitemid 32157962)
50. M.C. Trescol-Biemont, C. Verschelde, A. Cottalorda and N. Bonnefoy-Berard: Regulation of A1/Bfl-1 expression in peripheral splenic B cells. Biochimie 86(4-5), 287-94 (2004) (Pubitemid 38780834)
51. H. Hase, Y. Kanno, M. Kojima, K. Hasegawa, D. Sakurai, H. Kojima, N. Tsuchiya, K. Tokunaga, N. Masawa, M. Azuma, K. Okumura and T. Kobata: BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 103(6), 2257-65 (2004) (Pubitemid 38326245)
52. T. Zhou, J. Zhang, R. Carter and R. Kimberly: BLyS and B cell autoimmunity. Curr Dir Autoimmun 6, 21-37 (2003)
53. S.M. Tan, D. Xu, V. Roschke, J.W. Perry, D.G. Arkfeld, G.R. Ehresmann, T.S. Migone, D.M. Hilbert and W. Stohl: Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48(4), 982-92 (2003) (Pubitemid 36418240)
54. S.R. Dillon, J.A. Gross, S.M. Ansell and A.J. Novak: An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5(3), 235-46 (2006) (Pubitemid 43336036)
55. T.T. Lu and J.G. Cyster: Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 297(5580), 409-12 (2002) (Pubitemid 34790772)
56. M.T. de la Fuente, B. Casanova, J.V. Moyano, M. Garcia-Gila, L. Sanz, J. Garcia-Marco, A. Silva, A. Garcia-ardo, R. Minguez, A. Sempere, R. Arellano, J.L. Moyano, J. Sanz, J. Fraga, F.J. Melon and I. Pereira: Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 71(3), 495-502 (2002)
57. M.T. de la Fuente, B. Casanova, E. Cantero, M. Hernandez del Cerro, J. Garcia-Marco, A. Silva and A. Garcia-Pardo: Involvement of p53 in alpha4beta1 integrinmediated resistance of B-CLL cells to fludarabine. Biochem Biophys Res Commun 311(3), 708-12 (2003) (Pubitemid 37377714)
58. B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, F. Reyes, P.C. Lederlin, Gisselbrecht: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 346(4):235-42 (2002) (Pubitemid 34438862)
59. B. Pro, M.R. Smith, A. Younes, L.E. Fayad, A.H. Goy, F.B. Hagemeister, P. McLaughlin, M. Rodriguez, S.R. Frankel and J.A. Zwiebel: Oblimersen sodium (Bcl-2 antisense) plus rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma: Preliminary phase II result. ASCO 6572 (Abstract) (2004)
60. N. Baumgarth, O.C. Herman, G.C. Jager, L. Brown, L.A. Herzenberg and L.A. Herzenberg: Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Proc Natl Acad Sci U S A. 96(5), 2250-5 (1999) (Pubitemid 29117900)
61. G. Cambridge, M.J. Leandro, J.C. Edwards, M.R. Ehrenstein, M. Salden, M. Bodman-Smith and A.D. Webster: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48(8), 2146-54 (2003) (Pubitemid 36959194)
62. G. Cartron, H. Watier, J. Golay and P. Solal-Celigny: From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9):2635-42 (2004) (Pubitemid 39434941)
63. R.A. Clynes, T.L. Towers, L.G. Presta and J.V. Ravetch: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6(4), 443-6. (2000) (Pubitemid 30208162)
64. G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat and H. Watier: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3), 754-8 (2002) (Pubitemid 34525533)
65. S.S. Farag, I.W. Flinn, R. Modali, T.A. Lehman, D. Young and J.C. Byrd: Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in Bcell chronic lymphocytic leukemia. Blood 103(4), 1472-4 (2004) (Pubitemid 38168664)
66. H.R. Koene, M. Kleijer, A.J. Swaak, K.E. Sullivan, M. Bijl, M.A. Petri, C.G. Kallenberg, D. Roos, A.E. von dem Borne and M. de Haas: The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis Rheum 41(10), 1813-8 (1998) (Pubitemid 28465535)
67. J. Wu, J.C. Edberg, P.B. Redecha, V. Bansal, P.M. Guyre, K. Coleman, J.E. Salmon and R.P. Kimberly: A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100(5), 1059-70 (1997) (Pubitemid 27386289)
68. J.C. Edberg, C.D. Langefeld, J. Wu, K.L. Moser, K.M. Kaufman, J. Kelly, V. Bansal, W.M. Brown, J.E. Salmon, S.S. Rich, J.B. Harley and R.P. Kimberly: Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 46(8), 2132-40 (2002)
69. O. Manches, G. Lui, L. Chaperot, R. Gressin, J.P. Molens, M.C. Jacob, J. Sotto, D. Leroux, J.C. Bensa and J. Plumas: In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101(3), 949-54 (2003) (Pubitemid 36139365)
70. M.D. Carcao, V.S. Blanchette, C.D. Wakefield, D. Stephens, J. Ellis, K. Matheson and G.A. Denomme: Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 120(1), 135-41 (2003) (Pubitemid 36056921)
71. M.S. Cragg, S.M. Morgan, H.T. Chan, B.P. Morgan, A.V. Filatov, P. W. Johnson, R.R. French and M.J. Glennie: Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101(3), 1045-52 (2003) (Pubitemid 36139378)
72. A.D. Kennedy, P.V. Beum, M.D. Solga, D.J. DiLillo, M.A. Lindorfer, C. E. Hess, J.J. Densmore, M.E. Williams and R.P. Taylor: Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172(5), 3280-8 (2004) (Pubitemid 38263720)
73. N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna and J. Golay: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171(3), 1581-7 (2003) (Pubitemid 36900094)
74. M. Botto and M.J. Walport: C1q, autoimmunity and apoptosis. Immunobiology 205(4-5), 395-406 (2002) (Pubitemid 35153956)
75. B. Hellerstedt and A. Ahmed: Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol. 14(12), 1792 (2003) (Pubitemid 38029053)
76. F. Martin and A.C. Chan: Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20(5), 517-27 (2004) (Pubitemid 38638122)